[go: up one dir, main page]

AR065720A1 - Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. - Google Patents

Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.

Info

Publication number
AR065720A1
AR065720A1 ARP080101032A ARP080101032A AR065720A1 AR 065720 A1 AR065720 A1 AR 065720A1 AR P080101032 A ARP080101032 A AR P080101032A AR P080101032 A ARP080101032 A AR P080101032A AR 065720 A1 AR065720 A1 AR 065720A1
Authority
AR
Argentina
Prior art keywords
dispersed
tmc278
reconstitution
water
powers
Prior art date
Application number
ARP080101032A
Other languages
English (en)
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38055251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR065720(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of AR065720A1 publication Critical patent/AR065720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

4-[[4-[[4-(2-cianometil)-2,6-dimetil-fenil]amino]-2-pirimidinil]amino] benzonitrilo, polvos para reconstitucion que comprenden el NNRTI TMC278 (inhibidor no nucleosido de la transcriptasa inversa) disperso en ciertos polímeros solubles en agua, quepuede aplicarse en el tratamiento contra la infeccion por VIH. Proceso. Reivindicacion 1: El uso de un polvo que comprende TMC278, disperso en un polímero soluble en agua seleccionado entre polivinilpirrolidona, un copolímero de vinilpirrolidona yacetato de vinilo, una hidroxialquil alquilcelulosa, y un poloxámero, para mezclar con agua, para la fabricacion de un medicamento para el tratamiento de un sujeto infectado con VIH. Reivindicacion 5: Una solucion sobresaturada de TMC278, o unasal de adicion de ácido aceptable para uso farmacéutico del mismo, y un polímero soluble en agua seleccionado entre polivinilpirrolidona, un copolímero de vinilpirrolidona y acetato de vinilo, una hidroxialquil alquilcelulosa, y un poloxámero, en unmedio acuoso.
ARP080101032A 2007-03-14 2008-03-13 Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. AR065720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104082 2007-03-14

Publications (1)

Publication Number Publication Date
AR065720A1 true AR065720A1 (es) 2009-06-24

Family

ID=38055251

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080101032A AR065720A1 (es) 2007-03-14 2008-03-13 Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
ARP190100128A AR114086A2 (es) 2007-03-14 2019-01-21 Polvos para reconstitución

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190100128A AR114086A2 (es) 2007-03-14 2019-01-21 Polvos para reconstitución

Country Status (18)

Country Link
US (1) US8916558B2 (es)
EP (1) EP2043608B1 (es)
JP (1) JP5554571B2 (es)
KR (1) KR101580297B1 (es)
CN (1) CN101636149B (es)
AP (1) AP2964A (es)
AR (2) AR065720A1 (es)
AU (1) AU2008225774B2 (es)
BR (1) BRPI0808897B8 (es)
CA (1) CA2676981C (es)
CL (1) CL2008000746A1 (es)
ES (1) ES2535162T3 (es)
IL (1) IL199874A (es)
MX (1) MX2009009743A (es)
RU (1) RU2477133C2 (es)
TW (1) TWI494133B (es)
WO (1) WO2008110619A1 (es)
ZA (1) ZA200906344B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
PT2696848T (pt) 2011-04-15 2020-09-03 Janssen Pharmaceutica Nv Nanossuspensões de fármaco liofilizadas
JP6301339B2 (ja) * 2012-09-27 2018-03-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 少なくとも１種の水溶性ビタミンｅ誘導体および少なくとも１種の親水性ポリマーを含む、保存において安定な無塵の均質な粒子製剤
CA3144534A1 (en) * 2019-07-03 2021-01-07 Janssen Sciences Ireland Unlimited Company Methods of treating hiv in pediatric patients with rilpivirine
CN113440529B (zh) * 2020-03-25 2023-11-14 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
CN114392241B (zh) * 2022-01-10 2023-07-25 安徽贝克生物制药有限公司 一种利匹韦林片及其制备方法
TW202408580A (zh) * 2022-04-22 2024-03-01 愛爾蘭商健生科學愛爾蘭無限公司 冷凍乾燥組成物(二)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089818A (en) * 1960-06-02 1963-05-14 Baxter Laboratories Inc Water dispersible antibiotics
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
AU641267B2 (en) * 1990-07-19 1993-09-16 Otsuka Pharmaceutical Co., Ltd. Solid preparation
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
ATE184787T1 (de) 1992-05-13 1999-10-15 Wellcome Found Therapeutische kombinationen
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
JP2003509453A (ja) 1999-09-21 2003-03-11 アールティーピー・ファーマ・インコーポレーテッド 生物学的に活性な物質の、表面改質された粒状組成物
AP1639A (en) * 1999-09-24 2006-07-24 Janssen Pharmaceutica Nv Pharmaceutical compositions of antiviral compounds and processes for preparation.
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
US7135465B2 (en) 2000-03-30 2006-11-14 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
AU2002221096A1 (en) 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions improved in solublity in water
EP1404300B1 (en) 2001-06-22 2009-09-30 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) * 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
WO2003043586A2 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
CN100554245C (zh) 2002-08-09 2009-10-28 詹森药业有限公司 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
JP2006508134A (ja) 2002-11-08 2006-03-09 グラクソ　グループ　リミテッド 医薬組成物
AU2003296760B2 (en) 2002-11-15 2009-11-19 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EA011164B1 (ru) 2003-02-07 2009-02-27 Янссен Фармацевтика Н. В. Производные пиримидина для профилактики вич-инфекции
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
TWI389688B (zh) 2004-06-08 2013-03-21 Vertex Pharma Vx-950之形態與調配物及其製備方法與用途
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EA013686B1 (ru) 2004-09-02 2010-06-30 Янссен Фармацевтика Н.В. Гидрохлорид 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрила
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7910577B2 (en) 2004-11-16 2011-03-22 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) * 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
EP1872390A2 (en) * 2005-04-11 2008-01-02 The Board of Trustees of the Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
US20090142401A1 (en) 2005-06-07 2009-06-04 Leah Elizabeth Appel Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
WO2007014393A2 (en) 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
SI1981506T1 (sl) 2006-01-20 2013-08-30 Janssen R&D Ireland Dolgoročno zdravljenje infekcije HIV s TCM278
BRPI0712346B8 (pt) 2006-06-06 2021-05-25 Janssen R & D Ireland processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica
TWI413521B (zh) 2006-06-23 2013-11-01 Tibotec Pharm Ltd Ｔｍｃ２７８之水性懸浮液
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CA2693044C (en) 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Crystalline form of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Also Published As

Publication number Publication date
ES2535162T3 (es) 2015-05-05
KR101580297B1 (ko) 2015-12-24
CL2008000746A1 (es) 2008-09-22
KR20090119964A (ko) 2009-11-23
AR114086A2 (es) 2020-07-22
AU2008225774B2 (en) 2014-04-10
CN101636149A (zh) 2010-01-27
JP5554571B2 (ja) 2014-07-23
AP2964A (en) 2014-09-30
RU2009137911A (ru) 2011-04-20
IL199874A (en) 2016-02-29
WO2008110619A1 (en) 2008-09-18
US8916558B2 (en) 2014-12-23
CN101636149B (zh) 2014-08-06
RU2477133C2 (ru) 2013-03-10
BRPI0808897B8 (pt) 2021-05-25
EP2043608B1 (en) 2015-01-21
AP2009004969A0 (en) 2009-10-31
JP2010520918A (ja) 2010-06-17
BRPI0808897B1 (pt) 2020-10-20
TW200911303A (en) 2009-03-16
IL199874A0 (en) 2010-04-15
BRPI0808897A2 (pt) 2014-09-02
CA2676981A1 (en) 2008-09-18
AU2008225774A1 (en) 2008-09-18
CA2676981C (en) 2015-01-13
ZA200906344B (en) 2015-04-29
TWI494133B (zh) 2015-08-01
MX2009009743A (es) 2009-09-23
EP2043608A1 (en) 2009-04-08
US20100120795A1 (en) 2010-05-13

Similar Documents

Publication Publication Date Title
AR065720A1 (es) Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
KR101800564B1 (ko) 파프제 및 그 제조 방법
NZ599361A (en) A solid pharmaceutical dosage formulation
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
PH12019502566A1 (en) Pharmacologically active alicyclic-substituted pyrazolo[1,5-a] pyrimidine derivatives
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
FI2180887T3 (fi) Farmaseuttisia preparaatioita sisältäen voimakkaasti volatiilisia silikoneja
WO2013034927A8 (en) Compositions of lopinavir and ritonavir
MX2018009741A (es) Composicion farmaceutica que contiene un inhibidor de janus quinasa o una sal farmaceuticamente aceptable del mismo.
AR052153A1 (es) Composiciones y metodos para la estabilizacion de ingredientes farmaceuticos activos
AR059097A1 (es) Tratamiento a largo plazo de la infeccion por vih
JP6893075B2 (ja) 液性免疫誘導促進用組成物及びワクチン医薬組成物
NZ594618A (en) Transdermal pharmaceutical preparations
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP4306113A3 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
CN114761400A (zh) 一种可降解蛋白的并环类化合物及其应用
WO2005065656A3 (en) Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
MX2019015177A (es) Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
AR022250A1 (es) Envase farmaceutico de uso para el tratamiento y prevencion de infecciones por el virus de la hepatitis b, procedimiento para el tratamiento de pacientes o pacientes susceptibles en padecer infecciones por el virus de la hepatitis b.
MX2018004505A (es) Suspensiones orales fisica y quimicamente estables de givinostat.
NZ748394A (en) Oral and parenteral formulations of 2-(1,5-dimethyl-3-phenyl-1h-pyrrol-2-yl)-n-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
AR025341A1 (es) Composiciones farmaceuticas
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar

Legal Events

Date Code Title Description
FC Refusal